source
- Biogen's tau drug reports mixed Alzheimer's results, as low dose performs betterLONDON — Biogen's attempt to treat Alzheimer's by going after a protein that forms toxic tangles in the brain showed some of the strongest proof yet that it could slow dementia. But the results wer…Endpoints · 17d ago↗ source
- Biogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugsThe study provides the clearest evidence yet that medicines like BIIB080 might improve cognition, but leaves unclear why higher doses didn’t perform better.BioPharma Dive · 17d ago↗ source
- Draig nets $65M to advance depression drug aimed at rebuilding synapsesDraig Therapeutics has secured $65 million in an oversubscribed Series B raise to advance a pipeline of neuropsychiatry drugs, including its lead depression program designed to modulate the AMPA re…